Kevin J Harrington

List of Publications by Year
in descending order

148 papers	17,747 citations	46918 47 h-index	15683 125 g-index
152 all docs	152 docs citations	152 times ranked	18199 citing authors

#	Article	IF	Citations
1	Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. New England Journal of Medicine, 2016, 375, 1856-1867.	13.9	3,845
2	Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. Journal of Clinical Oncology, 2015, 33, 2780-2788.	0.8	1,988
3	Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet, The, 2019, 394, 1915-1928.	6.3	1,804
4	The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nature Reviews Cancer, 2015, 15, 409-425.	12.8	1,474
5	Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet, The, 2019, 393, 156-167.	6.3	1,153
6	Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nature Reviews Cancer, 2020, 20, 203-217.	12.8	420
7	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). , 2019, 7, 184.		413
8	Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncology, The, 2017, 18, 1104-1115.	5.1	325
9	Optimizing oncolytic virotherapy in cancer treatment. Nature Reviews Drug Discovery, 2019, 18, 689-706.	21.5	325
10	Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Science Translational Medicine, 2018, 10, .	5.8	288
11	Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncology, The, 2021, 22, 450-462.	5.1	287
12	Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage IIIâ€“IV melanoma. , 2019, 7, 145.		261
13	A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer. Clinical Cancer Research, 2008, 14, 7127-7137.	3.2	205
14	Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus. Clinical Cancer Research, 2008, 14, 259-269.	3.2	156
15	Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies. Clinical Cancer Research, 2012, 18, 2080-2089.	3.2	151
16	ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment. Clinical Cancer Research, 2019, 25, 3392-3403.	3.2	144
17	Cell Carriage, Delivery, and Selective Replication of an Oncolytic Virus in Tumor in Patients. Science Translational Medicine, 2012, 4, 138ra77.	5.8	142
18	A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epsteinâ€“Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive Cancer. Clinical Cancer Research, 2014, 20, 5009-5022.	3.2	139

#	Article	IF	Citations
19	Phase II Trial of Intravenous Administration of ReolysinÂ® (Reovirus Serotype-3-dearing Strain) in Patients with Metastatic Melanoma. Molecular Therapy, 2012, 20, 1998-2003.	3.7	135
20	Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nature Cancer, 2021, 2, 1305-1320.	5.7	123
21	Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. Frontiers in Oncology, 2017, 7, 72.	1.3	122
22	REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer. Clinical Cancer Research, 2010, 16, 5564-5572.	3.2	120
23	Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).. Journal of Clinical Oncology, 2019, 37, 6000-6000.	0.8	118
24	Radiation-induced carotid artery atherosclerosis. Radiotherapy and Oncology, 2014, 110, 31-38.	0.3	115
25	The Changing Landscape of Therapeutic Cancer Vaccinesâ€"Novel Platforms and Neoantigen Identification. Clinical Cancer Research, 2021, 27, 689-703.	3.2	113
26	Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: Rationale for future randomised trials in human papilloma virus-negative disease. European Journal of Cancer, 2013, 49, 1609-1618.	1.3	103
27	A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer. Clinical Cancer Research, 2011, 17, 581-588.	3.2	102
28	Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma. Nature Cancer, 2021, 2, 693-708.	5.7	102
29	The MRI-Linear Accelerator Consortium: Evidence-Based Clinical Introduction of an Innovation in Radiation Oncology Connecting Researchers, Methodology, Data Collection, Quality Assurance, and Technical Development. Frontiers in Oncology, 2016, 6, 215.	1.3	100
30	Tipifarnib in Head and Neck Squamous Cell Carcinoma WithHRASMutations. Journal of Clinical Oncology, 2021, 39, 1856-1864.	0.8	100
31	Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. Nature Biotechnology, 2012, 30, 337-343.	9.4	98
32	Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei. Molecular Cancer Therapeutics, 2017, 16, 25-34.	1.9	93
33	Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nature Medicine, 2011, 17, 854-859.	15.2	86
34	Applications of coxsackievirus A21 in oncology. Oncolytic Virotherapy, 2014, 3, 47.	6.0	84
35	Synergistic Effects of Oncolytic Reovirus and Cisplatin Chemotherapy in Murine Malignant Melanoma. Clinical Cancer Research, 2009, 15, 6158-6166.	3.2	83
36	Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial. OncoTargets and Therapy, 2016, Volume 9, 7081-7093.	1.0	83

#	Article	IF	Citations
37	Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. Journal of Clinical Oncology, 2022, 40, 2321-2332.	0.8	79
38	Oncolytic virusâ€“mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice. Science Translational Medicine, 2022, 14, eabn2231.	5.8	70
39	Comparison of CT number calibration techniques for CBCT-based dose calculation. Strahlentherapie Und Onkologie, 2015, 191, 970-978.	1.0	66
40	Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. Nature Cancer, 2021, 2, 1321-1337.	5.7	66
41	Novel approaches to improve the therapeutic index of head and neck radiotherapy: An analysis of data from the PARSPORT randomised phase III trial. Radiotherapy and Oncology, 2012, 103, 82-87.	0.3	65
42	Improved Systemic Delivery of Oncolytic Reovirus to Established Tumors Using Preconditioning with Cyclophosphamide-Mediated Treg Modulation and Interleukin-2. Clinical Cancer Research, 2009, 15, 561-569.	3.2	63
43	Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer. Modern Pathology, 2021, 34, 532-541.	2.9	63
44	Cytokine Conditioning Enhances Systemic Delivery and Therapy of an Oncolytic Virus. Molecular Therapy, 2014, 22, 1851-1863.	3.7	60
45	Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study. Clinical Cancer Research, 2020, 26, 5153-5161.	3.2	58
46	Treatment-related dysgeusia in head and neck cancer patients. Cancer Treatment Reviews, 2014, 40, 1106-1117.	3.4	57
47	Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer, 2011, 11, 221.	1.1	52
48	Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence. Nature Medicine, 2013, 19, 1625-1631.	15.2	52
49	Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway. BMC Cancer, 2012, 12, 368.	1.1	49
50	Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyteâ€macrophage colonyâ€stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma. Head and Neck, 2016, 38, 1752-1758.	0.9	49
51	Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer. Gut, 2018, 67, 562-573.	6.1	49
52	Human Papillomavirusâ€“Negative Pharyngeal Cancer. Journal of Clinical Oncology, 2015, 33, 3251-3261.	0.8	47
53	Nearâ€infrared photoimmunotherapy targeting EGFRâ€”Shedding new light on glioblastoma treatment. International Journal of Cancer, 2018, 142, 2363-2374.	2.3	47
54	APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy. Nature Communications, 2020, 11, 790.	5.8	47

#	Article	IF	Citations
55	CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy. Molecular Cancer Therapeutics, 2016, 15, 2042-2054.	1.9	46
56	BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress. Molecular Therapy, 2015, 23, 931-942.	3.7	44
57	NUT Carcinoma of the Salivary Glands. American Journal of Surgical Pathology, 2018, 42, 877-884.	2.1	44
58	Impact of antibiotic use during curative treatment of locally advanced head and neck cancers with chemotherapy and radiotherapy. European Journal of Cancer, 2020, 131, 9-15.	1.3	44
59	Phase I Trial of Cyclophosphamide as an Immune Modulator for Optimizing Oncolytic Reovirus Delivery to Solid Tumors. Clinical Cancer Research, 2015, 21, 1305-1312.	3.2	40
60	The emerging potential of magnetic resonance imaging in personalizing radiotherapy for head and neck cancer: an oncologist's perspective. British Journal of Radiology, 2017, 90, 20160768.	1.0	39
61	Multiple cervical lymph node involvement and extra-capsular extension predict for contralateral nodal recurrence after ipsilateral radiotherapy for squamous cell carcinoma of the tonsil. Oral Oncology, 2014, 50, 901-906.	0.8	37
62	Evaluation of the Risk of Grade 3 Oral and Pharyngeal Dysphagia Using Atlas-Based Method and Multivariate Analyses of Individual Patient Dose Distributions. International Journal of Radiation Oncology Biology Physics, 2015, 93, 507-515.	0.4	36
63	Head and neck mucosal melanoma: The United Kingdom national guidelines. European Journal of Cancer, 2020, 138, 11-18.	1.3	36
64	Harnessing radiotherapy-induced NK-cell activity by combining DNA damageâ€“response inhibition and immune checkpoint blockade. , 2022, 10, e004306.		36
65	Functional Cloning of Recurrence-specific Antigens Identifies Molecular Targets to Treat Tumor Relapse. Molecular Therapy, 2013, 21, 1507-1516.	3.7	35
66	Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck. JAMA Oncology, 2019, 5, 1170.	3.4	34
67	A practical guide to the handling and administration of talimogene laherparepvec in Europe. OncoTargets and Therapy, 2017, Volume 10, 3867-3880.	1.0	33
68	Further evaluations of nivolumab (nivo) versus investigatorâ€™s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141.. Journal of Clinical Oncology, 2016, 34, 6009-6009.	0.8	32
69	Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer. European Journal of Cancer, 2020, 136, 99-106.	1.3	31
70	Vesicular Stomatitis Virus-induced Immune Suppressor Cells Generate Antagonism Between Intratumoral Oncolytic Virus and Cyclophosphamide. Molecular Therapy, 2011, 19, 140-149.	3.7	30
71	A randomised controlled trial of Caphosol mouthwash in management of radiation-induced mucositis in head and neck cancer. Radiotherapy and Oncology, 2017, 122, 207-211.	0.3	27
72	Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21. , 2019, 7, 164.		27

#	Article	IF	Citations
73	On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy. , 2021, 9, e002718.		23
74	Subversion of NK-cell and TNFÎ± Immune Surveillance Drives Tumor Recurrence. Cancer Immunology Research, 2017, 5, 1029-1045.	1.6	22
75	Principal component analysis for fast and model-free denoising of multi b-value diffusion-weighted MR images. Physics in Medicine and Biology, 2019, 64, 105015.	1.6	22
76	Oncolytic vaccinia virus combined with radiotherapy induces apoptotic cell death in sarcoma cells by down-regulating the inhibitors of apoptosis. Oncotarget, 2016, 7, 81208-81222.	0.8	22
77	Final long-term results of a phase I/II study of dose-escalated intensity-modulated radiotherapy for locally advanced laryngo-hypopharyngeal cancers. Oral Oncology, 2014, 50, 1089-1097.	0.8	21
78	Arterial Stiffness as a Biomarker of Radiation-Induced Carotid Atherosclerosis. Angiology, 2016, 67, 266-271.	0.8	21
79	Abstract CT115: Updated survival results of the KEYNOTE-040 study of pembrolizumab vs standard-of-care chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma. Cancer Research, 2018, 78, CT115-CT115.	0.4	21
80	Blood transfusion during radical chemo-radiotherapy does not reduce tumour hypoxia in squamous cell cancer of the head and neck. British Journal of Cancer, 2017, 116, 28-35.	2.9	20
81	Immunomodulatory activity of IR700-labelled affibody targeting HER2. Cell Death and Disease, 2020, 11, 886.	2.7	20
82	KEYNOTE-040: A phase III randomized trial of pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer.. Journal of Clinical Oncology, 2015, 33, TPS6084-TPS6084.	0.8	20
83	Safety and preliminary efficacy of talimogene laherparepvec (T-VEC) in combination (combo) with pembrobrolizumab (Pembro) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): A multicenter, phase 1b study (MASTERKEY-232).. Journal of Clinical Oncology, 2018, 36, 6036-6036.	0.8	20
84	Brain-Sparing Methods for IMRT of Head and Neck Cancer. PLoS ONE, 2015, 10, e0120141.	1.1	19
85	Carotid intima-medial thickness as a marker of radiation-induced carotid atherosclerosis. Radiotherapy and Oncology, 2016, 118, 323-329.	0.3	18
86	Final analysis: A randomized, blinded, placebo (P)-controlled phase III study of adjuvant postoperative lapatinib (L) with concurrent chemotherapy and radiation therapy (CH-RT) in high-risk patients with squamous cell carcinoma of the head and neck (SCCHN).. Journal of Clinical Oncology, 2014, 32, 6005-6005.	0.8	17
87	Warthin Tumorâ€"Like Mucoepidermoid Carcinoma. International Journal of Surgical Pathology, 2018, 26, 31-33.	0.4	16
88	Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States. Journal of Medical Economics, 2020, 23, 442-447.	1.0	16
89	Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective. , 2020, 8, e000648.		15
90	Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy. BMC Medicine, 2022, 20, 16.	2.3	15

#	Article	IF	Citations
91	The Profile of Tumor Antigens Which Can be Targeted by Immunotherapy Depends Upon the Tumor's Anatomical Site. Molecular Therapy, 2014, 22, 1936-1948.	3.7	14
92	Plaque Neovascularization Is Increased inÂHuman Carotid Atherosclerosis RelatedÂto Prior Neck Radiotherapy. JACC: Cardiovascular Imaging, 2016, 9, 668-675.	2.3	14
93	Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR;) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50	1.3	14
94	APOBEC3 Mediates Resistance to Oncolytic Viral Therapy. Molecular Therapy - Oncolytics, 2018, 11, 1-13.	2.0	14
95	A phase 3, randomized, open-label study of epacadostat plus pembrolizumab, pembrolizumab monotherapy, and the EXTREME regimen as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M SCCHN): ECHO-304/KEYNOTE-669.. Journal of Clinical Oncology, 2018, 36, TPS6090-TPS6090.	0.8	14
96	Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment. Cancer Immunology Research, 2019, 7, 828-840.	1.6	13
97	A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma. European Journal of Cancer, 2013, 49, 2512-2521.	1.3	11
98	Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory Agents. Molecular Therapy, 2015, 23, 845-856.	3.7	11
99	Optimal acquisition scheme for flowâ€compensated intravoxel incoherent motion diffusionâ€weighted imaging in the abdomen: An accurate and precise clinically feasible protocol. Magnetic Resonance in Medicine, 2020, 83, 1003-1015.	1.9	11
100	Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer. , 2020, 8, e000698.		11
101	Attenuation Correction and Normalisation for Quantification of Contrast Enhancement in Ultrasound Images of Carotid Arteries. Ultrasound in Medicine and Biology, 2015, 41, 1876-1883.	0.7	10
102	Acoustic parameters of speech: Lack of correlation with perceptual and questionnaireâ€based speech evaluation in patients with oral and oropharyngeal cancer treated with primary surgery. Head and Neck, 2016, 38, 670-676.	0.9	10
103	Abstract LB-258: Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score <1, 1-19, and â‰¥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis. Cancer Research, 2020, 80, LB-258-LB-258.	0.4	10
104	Nivolumab (nivo) vs investigatorâ€™s choice (IC) in patients (pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Analysis of CheckMate 141 by age.. Journal of Clinical Oncology, 2018, 36, 6028-6028.	0.8	9
105	Abstract CT084: A Phase I dose-escalation study of ATR inhibitor monotherapy with AZD6738 in advanced solid tumors (PATRIOT Part A). Cancer Research, 2017, 77, CT084-CT084.	0.4	8
106	Contrast enhancement of carotid adventitial vasa vasorum as a biomarker of radiation-induced atherosclerosis. Radiotherapy and Oncology, 2016, 120, 63-68.	0.3	7
107	Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy. Nature Communications, 2021, 12, 1930.	5.8	7
108	Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trial. European Journal of Cancer, 2021, 153, 242-256.	1.3	7

#	Article	IF	Citations
109	Abstract CT118: PK-Biomarker-Safety modelling aids choice of recommended Phase II dose and schedule for AZD6738 (ATR inhibitor). Cancer Research, 2018, 78, CT118-CT118.	0.4	7
110	Characterization of potential predictive biomarkers of response to nivolumab in CheckMate 141 in patients with squamous cell carcinoma of the head and neck (SCCHN).. Journal of Clinical Oncology, 2017, 35, 6050-6050.	0.8	7
111	Randomized phase 2 trial of patritumab (P) or placebo (PBO) + cetuximab (C) + cisplatin (CIS) or carboplatin (CAR) for recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).. Journal of Clinical Oncology, 2018, 36, 6045-6045.	0.8	7
112	Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital. JCO Clinical Cancer Informatics, 2022, , .	1.0	7
113	Combining Molecularly Targeted Agents: Is More Always Better?. Clinical Cancer Research, 2017, 23, 1123-1125.	3.2	6
114	Dosimetric Implications of Computerised Tomography-Only versus Magnetic Resonance-Fusion Contouring in Stereotactic Body Radiotherapy for Prostate Cancer. Medicines (Basel, Switzerland), 2018, 5, 32.	0.7	5
115	Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies. , 2021, 9, e002673.		5
116	Phase I/II canon study: Oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical coxsackievirus A21.. Journal of Clinical Oncology, 2016, 34, e16016-e16016.	0.8	5
117	Phase I/II storm study: Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21, in advanced cancer patients. , 2015, 3, P341.		4
118	ORCA-2: A phase I study of olaparib in addition to cisplatin-based concurrent chemoradiotherapy for patients with high risk locally advanced squamous cell carcinoma of the head and neck.. Journal of Clinical Oncology, 2016, 34, TPS6108-TPS6108.	0.8	4
119	Abstract CT116: Nivolumab (Nivo) vs investigator's choice (IC) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): 2-yr outcomes in the overall population and PD-L1 subgroups of CheckMate 141. Cancer Research, 2018, 78, CT116-CT116.	0.4	4
120	Using a Bayesian Feature-selection Algorithm to Identify Dose-response Models Based on the Shape of the 3D Dose-distribution: An Example from a Head-and-neck Cancer Trial. , 2010, , .		3
121	Contrast-enhanced ultrasound to assess plaque neovascularization in irradiated carotid arteries. International Journal of Cardiology, 2016, 202, 3-4.	0.8	3
122	Abstract LB180: Clinical biomarker studies with two fusion-enhanced versions of oncolytic HSV (RP1) Tj ETQq0 0 0 rgBT /Overlock 10 Tf activation. Cancer Research, 2021, 81, LB180-LB180.	0.4	3
123	Abstract CT205: Intravenous delivery of a novel oncolytic immunotherapy agent, CAVATAK, in advanced cancer patients. Cancer Research, 2015, 75, CT205-CT205.	0.4	3
124	Phase I STORM study (KEYNOTE 200): Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients.. Journal of Clinical Oncology, 2016, 34, TPS3108-TPS3108.	0.8	3
125	Progression-free survival (PFS) in unresectable melanoma patients (pts) treated with talimogene laherparepvec (T-VEC) versus granulocyte macrophage colony-stimulating factor (GM-CSF) in OPTiM.. Journal of Clinical Oncology, 2019, 37, 9524-9524.	0.8	3
126	CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma. , 2022, 10, e004410.		3

#	Article	IF	Citations
127	MET and RON Receptor Tyrosine Kinases: Novel Therapeutic Targets in Squamous Cell Carcinoma of the Head and Neck. Current Enzyme Inhibition, 2007, 3, 1-12.	0.3	2
128	69. Combination Therapy of Reovirus and PD-1 Blockade Effectively Establishes Tumor Control Via Innate and Adaptive Immune Responses. Molecular Therapy, 2015, 23, S30.	3.7	2
129	PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours.. Journal of Clinical Oncology, 2016, 34, TPS2603-TPS2603.	0.8	2
130	Patritumab (P) or placebo (PBO) plus cetuximab (C) and platinum-based therapy in squamous cell carcinoma of the head and neck (SCCHN): a phase 2 study.. Journal of Clinical Oncology, 2016, 34, TPS6104-TPS6104.	0.8	2
131	Pembrolizumab (pembro) for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of phase 3 KEYNOTE-040 prior radiation treatment (RT) and disease state.. Journal of Clinical Oncology, 2019, 37, 6026-6026.	0.8	2
132	Abstract 1360: Combination therapy of reovirus and PD-1 blockade effectively establishes tumor control via innate and adaptive immune responses. , 2015, , .		2
133	An open label, multicenter, phase I/II study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors.. Journal of Clinical Oncology, 2019, 37, TPS2671-TPS2671.	0.8	2
134	Management of Head and Neck Mucosal Melanoma. Oral and Maxillofacial Surgery Clinics of North America, 2022, 34, 299-314.	0.4	2
135	Targeting ATR for Cancer Therapy: ATR-Targeted Drug Candidates. Cancer Drug Discovery and Development, 2018, , 99-127.	0.2	1
136	Abstract 3100: HOX transcription factors promote cell survival in breast cancer. Cancer Research, 2011, 71, 3100-3100.	0.4	1
137	Oncolytic wild-type reovirus infection in brain tumors following intravenous administration in patients.. Journal of Clinical Oncology, 2014, 32, 3104-3104.	0.8	1
138	First results of COSTAR: A randomised trial of 3-dimensional conformal radiotherapy (3DCRT) vs cochlea-sparing intensity modulated radiotherapy (CS-IMRT) in patients with parotid cancer.. Journal of Clinical Oncology, 2016, 34, 6006-6006.	0.8	1
139	Characterization of potential predictive biomarkers of response to nivolumab in CheckMate-141 in patients with squamous cell carcinoma of the head and neck (SCCHN).. Journal of Clinical Oncology, 2017, 35, 5-5.	0.8	1
140	408â€...Phase I, first-in-human trial evaluating BI 1387446 (stimulator of interferon genes [STING] agonist) alone and combined with BI 754091 (anti-programmed cell death [PD]-1) in solid tumors. , 2020, , .		1
141	63. Immunogenicity of Self Tumor Associated Antigens Is Enhanced Through Protein Truncation. Molecular Therapy, 2016, 24, S28.	3.7	0
142	Reply to N.F. Saba and S.J. Wong. Journal of Clinical Oncology, 2016, 34, 2073-2074.	0.8	0
143	Predicting response to radical (chemo)radiotherapy (R-CRT) with circulating HPV DNA and tumor DNA (ctDNA) analysis in locally-advanced head and neck squamous cell carcinoma (LAHNC).. Journal of Clinical Oncology, 2017, 35, 6043-6043.	0.8	0
144	Molecular prediction of lymph node metastases using immunohistochemical analysis of primary oral tongue squamous cell carcinomas.. Journal of Clinical Oncology, 2018, 36, 6054-6054.	0.8	0

#	Article	IF	Citations
145	Hope for salivary gland cancer (SGC): EORTC HNCG/UKCRN 1206 randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) inpatients with recurrent and/or metastatic androgen receptor (AR) expressing SGC (NCT01969578).. Journal of Clinical Oncology, 2018, 36, TPS6099-TPS6099.	0.8	0
146	Abstract 4162: Lentivirally delivered shRNA knockdown of CXCL12 is effective at preventing radiation fibrosis in normal tissues. , 2018, , .		0
147	Abstract LB-104: Quantification of the preclinical and clinical relationship between pRAD50 and efficacy after treatment with the ATR inhibitor ceralasertib (AZD6738). , 2020, , .		0
148	439â€…A phase 2 study of evorpacept (ALX148) in combination with pembrolizumab in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-03. , 2021, 9, A469-A469.		0